Abstract:Acute Myeloid Leukemia (AML) is a type of cancer of the blood system that is characterized by an accumulation of immature hematopoietic cells in the bone marrow and blood. Its pathogenesis is characterized by an increase in self-renewal and block in differentiation in hematopoietic stem and progenitor cells. Underlying its pathogenesis is the acquisition of mutations in these cells. As there are many different mutations found in AML that can occur in different combinations the disease is very heterogeneous. There has been some progress in the treatment of AML through the introduction of targeted therapies and a broader application of the stem cell transplantation in its treatment. However, many mutations found in AML are still lacking defined interventions. These are in particular mutations and dysregulation in important myeloid transcription factors and epigenetic regulators that also play a crucial role in normal hematopoietic differentiation. While a direct targeting of the partial loss-of-function or change in function observed in these factors is very difficult to imagine, recent data suggests that the inhibition of LSD1, an important epigenetic regulator, can modulate interactions in the network of myeloid transcription factors and restore differentiation in AML. Interestingly, the impact of LSD1 inhibition in this regard is quite different between normal and malignant hematopoiesis. The effect of LSD1 inhibition involves transcription factors that directly interact with LSD1 such as GFI1 and GFI1B, but also transcription factors that bind to enhancers that are modulated by LSD1 such as PU.1 and C/EBPα as well as transcription factors that are regulated downstream of LSD1 such as IRF8. In this review, we are summarizing the current literature on the impact of LSD1 modulation in normal and malignant hematopoietic cells and the current knowledge how the involved transcription factor networks are altered. We are also exploring how these modulation of transcription factors play into the rational selection of combination partners with LSD1 inhibitors, which is an intense area of clinical investigation.

An autoinhibitory switch of the LSD1 disordered region controls enhancer silencing

Demethylase-independent roles of LSD1 in regulating enhancers and cell fate transition

A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation.

Opposing LSD1 Complexes Function in Developmental Gene Activation and Repression Programmes

Regulation of LSD1 histone demethylase activity by its associated factors.

Short Article Regulation of LSD1 Histone Demethylase Activity by Its Associated Factors

LSD1n is an H4K20 Demethylase Regulating Memory Formation Via Transcriptional Elongation Control

Conserved helical motifs in the IKZF1 disordered region mediate NuRD interaction and transcriptional repression

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia

Structure-function Analysis Reveals a Novel Mechanism for Regulation of Histone Demethylase LSD2/AOF1/KDM1b.

Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1

Autoregulatory mechanism of enzyme activity by the nuclear localization signal of lysine-specific demethylase 1

The Cross-Regulation Between Set1, Clr4, and Lsd1/2 in Schizosaccharomyces pombe

Pro Isomerization in Mll1 Phd3-Bromo Cassette Connects H3k4me Readout to Cyp33 and Hdac-Mediated Repression

A Partially Disordered Region Connects Gene Repression and Activation Functions of EZH2

LSD1 inhibition modulates transcription factor networks in myeloid malignancies

Recognition of Unmethylated Histone H3 Lysine 4 Links BHC80 to LSD1-mediated Gene Repression

Mechanism for DPY30 and ASH2L intrinsically disordered regions to modulate the MLL/SET1 activity on chromatin

Human Lsd2/Kdm1b/Aof1 Regulates Gene Transcription by Modulating Intragenic H3k4me2 Methylation

Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.

LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML